CAJ | 학술논문

目的：研究早期使用乌司他丁治疗多发伤全身炎症反应综合征(SIRS)的效果。方法选择多发伤患者71例，分为对照组34例、观察组37例；两组均行常规对症治疗；观察组加用乌司他丁针，疗程5 d；动态观察两组入院5 d(120 h)血清炎症因子(TNF-α、IL-6、IL-8)变化及总住院时间、ICU住院时间、28 d病死率。结果血清炎症因子浓度观察组24 h内逐渐升高，而后逐步下降(P<0.05)，对照组持续升高(P<0.05)，观察组治疗后各时间段血清炎症因子值均小于对照组(P<0.05)；观察组总住院时间、ICU住院时间明显少于对照组(P<0.05)；但两组28 d病死率比较差异无统计学意义(P>0.05)。结论乌司他丁可减轻多发伤患者炎症反应，缩短总住院时间、ICU住院时间，但对其死亡率无明显影响。
목적：연구조기사용오사타정치료다발상전신염증반응종합정(SIRS)적효과。방법선택다발상환자71례，분위대조조34례、관찰조37례；량조균행상규대증치료；관찰조가용오사타정침，료정5 d；동태관찰량조입원5 d(120 h)혈청염증인자(TNF-α、IL-6、IL-8)변화급총주원시간、ICU주원시간、28 d병사솔。결과혈청염증인자농도관찰조24 h내축점승고，이후축보하강(P<0.05)，대조조지속승고(P<0.05)，관찰조치료후각시간단혈청염증인자치균소우대조조(P<0.05)；관찰조총주원시간、ICU주원시간명현소우대조조(P<0.05)；단량조28 d병사솔비교차이무통계학의의(P>0.05)。결론오사타정가감경다발상환자염증반응，축단총주원시간、ICU주원시간，단대기사망솔무명현영향。
Objective To evaluate the effect of earlier using ulinastatin for SIRS of patients with multi-injure. Methods A total of 71 patients with multi-injure were divided into two groups:the inspecting group and control group. 37,34 cas-es respectively. The two groups were treated according to the therapy guidelines of multi-injure.Besides taking the ma-noeuvres same as the contrast group, the inspecting group were added ulinastatin for 5 days;The blood concentration of inflammatory factors included Tumor necrosis factor-alpha (TNF-α), Interleukin-6 (IL-6), Interleukin-8 (IL-8) were measured. The days in ICU, the avarege days of stay hospital and the 28-day fatality rate were compared. Results During the first 24 h, the level of inflammatory factors in plasma of the inspecting group elevated, and after that time they decreased continuously. In control group, the level of inflammatory factors in plasma were increased continuously in the every measure times, and had a significont difference between the two groups(P<0.05). The days in ICU, the av-erage days of stay hospital of inspecting group were shorter than that of the contrast group(P<0.05). But the 28-day fa-tality rate didn’t have significant difference in the two groups (P>0.05).Conclusion Using ulinastatin could alleviated SIRS of patients with multi-injure, and can decrease the days in ICU and the average day of stay hospital. But it can not change the 28-day fatality rate.